Alector Inc. Stock News

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arb

The following slide deck was published by Alector, Inc. in conjunction with this event..

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) Avenue Therapeutics Inc (NASDAQ: ATXI) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) DarioHealth Corp (NASDAQ:...

Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

* Pivotal Phase 3 trial of AL001 initiated for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) * Promising preliminary data from AL001 Phase 1b and Phase 2 open-

SG Americas Securities LLC grew its stake in Alector Inc (NASDAQ:ALEC) by 35.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The insti

Orchard Therapeutics plc (NASDAQ:ORTX) Q2 2020 Results Conference Call August 06, 2020 08:00 AM ET Company Participants Renee Leck - Investor Relations Bobby Gaspar - Chief Executive Officer Frank Tho

Alector released preliminary data from its ongoing Phase 2 trial of AL001 in frontotemporal dementia on July 28.

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D.

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Fulgent Genetics Inc (NASDAQ: FLGT

The following slide deck was published by Alector, Inc. in conjunction with this event..